WO2024252368 - METHODS AND COMPOSITIONS FOR TREATING ULCERATIVE COLITIS
National phase entry is expected:
Publication Number
WO/2024/252368
Publication Date
12.12.2024
International Application No.
PCT/IB2024/055621
International Filing Date
08.06.2024
Title **
[English]
METHODS AND COMPOSITIONS FOR TREATING ULCERATIVE COLITIS
[French]
PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
PARASKEVOPOULOU, Maria
FESTEN, Eleonora A.M.
BIGAEVA, Emilia
Priority Data
63/507,369
09.06.2023
US
63/590,182
13.10.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5860 | |
| EPO | Filing, Examination, Granting | 48606 | |
| Japan | Filing, Examination, Granting | 3571 | |
| South Korea | Filing, Examination, Granting | 4995 | |
| USA | Filing, Examination, Granting | 15190 |
Total:
78,222
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides methods and compositions related to methods for determining whether a human subject having ulcerative colitis will respond to treatment with a humanized antibody having binding specificity for human α4β7 integrin for treating ulcerative colitis. The invention provides response markers that can be used to identify responders of ulcerative colitis.[French]
L'invention concerne des procédés et des compositions associés à des procédés pour déterminer si un sujet humain ayant une rectocolite hémorragique répondra à un traitement avec un anticorps humanisé ayant une spécificité de liaison pour l'intégrine α4β7 humaine afin de traiter la rectocolite hémorragique. L'invention concerne des marqueurs de réponse qui peuvent être utilisés pour identifier des sujets répondeurs atteints de colite ulcéreuse.